Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Shenzhen Neptunus Interlong Bio-Technique Co Cash Conversion Cycle Related Terms
Shenzhen Neptunus Interlong Bio-Technique Co Cash Conversion Cycle Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen Neptunus Interlong Bio-Technique Co Cash Conversion Cycle Chart
Shenzhen Neptunus Interlong Bio-Technique Co Annual Data
HKSE:08329 vs ZTS: Cash Conversion Cycle Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhen Neptunus Interlong Bio-Technique Co's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shenzhen Neptunus Interlong Bio-Technique Co Cash Conversion Cycle vs Drug Manufacturers Industry
Shenzhen Neptunus Interlong Bio-Technique Co Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) has a Cash Conversion Cycle of 43.07 as of Jun. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Shenzhen Neptunus Interlong Bio-Technique Co and its competitors.
Is Shenzhen Neptunus Interlong Bio-Technique Co's Cash Conversion Cycle too high?
Shenzhen Neptunus Interlong Bio-Technique Co's current Cash Conversion Cycle is 43.07. The Drug Manufacturers industry median Cash Conversion Cycle is 145.82. Shenzhen Neptunus Interlong Bio-Technique Co's value of 43.07 is 70.5% below this industry median. Overall, Shenzhen Neptunus Interlong Bio-Technique Co has a GF Score™ of 48/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shenzhen Neptunus Interlong Bio-Technique Co's Cash Conversion Cycle compare to ZTS?
Shenzhen Neptunus Interlong Bio-Technique Co's Cash Conversion Cycle of 43.07 can be compared against companies in the Drug Manufacturers industry. The industry median Cash Conversion Cycle is 145.82. Shenzhen Neptunus Interlong Bio-Technique Co's value of 43.07 is 70.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Drug Manufacturers company?
The median Cash Conversion Cycle among Drug Manufacturers companies is 145.82, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shenzhen Neptunus Interlong Bio-Technique Co's current Cash Conversion Cycle of 43.07 is 70.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Shenzhen Neptunus Interlong Bio-Technique Co and its competitors. For the Drug Manufacturers industry, the median Cash Conversion Cycle is 145.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shenzhen Neptunus Interlong Bio-Technique Co's current Cash Conversion Cycle is 43.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen Neptunus Interlong Bio-Technique Co stock overvalued right now?
Based on GuruFocus' analysis, Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.14, compared to a current price of HK$0.11 — trading 25% below its estimated fair value. The current Cash Conversion Cycle is 43.07 and 70.5% below the Drug Manufacturers industry median of 145.82. Shenzhen Neptunus Interlong Bio-Technique Co's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329), the current Cash Conversion Cycle is 43.07 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) Overvalued in 2026?
Based on GuruFocus' analysis, Shenzhen Neptunus Interlong Bio-Technique Co stock appears to be undervalued.
The current stock price of HK$0.11 is trading 25% below its estimated GF Value™ of HK$0.14.
GuruFocus considers Shenzhen Neptunus Interlong Bio-Technique Co to be Modestly Undervalued.
Key valuation signals for HKSE:08329:
Cash Conversion Cycle: 43.07
GF Value™: HK$0.14 vs. price of HK$0.11 (25% below fair value)
Industry Position: 70.5% below the Drug Manufacturers median
No single metric tells the full story. See the HKSE:08329 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shenzhen Neptunus Interlong Bio-Technique Co Ltd is engaged in the research and development, manufacturing, and selling of medicines and medical devices. It is also involved in the purchase and sale of medicines and healthcare food products. The group's revenue and results from operations are mainly derived from activities in the PRC. The operating segments of the company are the Manufacturing and selling of medicines and medical devices; and the Sales and distribution of medicines, healthcare products, and medical devices.. The majority of revenue is generated from the Manufacturing and selling of medicines and medical devices segment.
48GF Score
Get the complete analysis for HKSE:08329
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08329 has been successfully added to your 
